Michael Gelband’s Adaptimmune Therapeutics ADAP Stock Holding History

Michael Gelband’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-370,288	Closed	-$398K	–	1587
2022 Q3	$398K	Buy	370,288 +70,288	+23%	+$129K	0.01%	1441
2022 Q2	$510K	Buy	+300,000	New	+$515K	0.01%	1339
2021 Q4	–	Sell	-86,202	Closed	-$446K	–	2119
2021 Q3	$446K	Buy	+86,202	New	+$387K	0.01%	1459
2021 Q1	–	Sell	-76,920	Closed	-$415K	–	2072
2020 Q4	$415K	Buy	76,920 +46,313	+151%	+$252K	﹤0.01%	1358
2020 Q3	$244K	Buy	+30,607	New	+$268K	﹤0.01%	1385

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Michael Gelband's ADAP Position: Q4 2022 in Review

Michael Gelband sold out of Adaptimmune Therapeutics (ADAP) in Q4 2022, closing a stake of 370,288 shares — an estimated $398K sold.

Michael Gelband first reported a position in ADAP in Q3 2020 and held it in 5 quarters. The position peaked at $510K in Q2 2022. 69 funds tracked by Wall St. Rank hold ADAP as of Q4 2022.

Michael Gelband reported no remaining Adaptimmune Therapeutics position as of Q4 2022 after selling out during the quarter.
Michael Gelband sold 370,288 Adaptimmune Therapeutics shares in Q4 2022, an estimated $398K.
Michael Gelband first reported a position in Adaptimmune Therapeutics in Q3 2020 and held it in 5 quarters.
Michael Gelband's Adaptimmune Therapeutics position peaked at $510K in Q2 2022.
69 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2022.

Based on ExodusPoint Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.